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Abstract
Approximately 15–40% of all cancers develop metastases in the central nervous system (CNS), yet 
few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are 
widely successful, yet have limited efficacy against CNS metastases, owing to the low levels of the 
drug reaching the tumour site. Here, we show that the encapsulation of rituximab within a 
crosslinked zwitterionic polymer layer leads to the sustained release of rituximab as the 
crosslinkers are gradually hydrolyzed, enhancing by approximately 10-fold the CNS levels of the 
antibody with respect to the administration of naked rituximab. When the nanocapsules are 
functionalized with CXCL13, the ligand for the chemokine receptor CXCR5 frequently found on 
B-cell lymphoma, a single dose led to improved control of CXCR5-expressing metastases in a 
murine xenograft model of non-Hodgkin lymphoma, and eliminated lymphoma in a xenografted 
humanized bone-marrow–liver–thymus mouse model. Encapsulation and molecular targeting of 
therapeutic antibodies could become an option for the treatment of cancers with CNS metastases.
Treatments for cancer metastases, especially those of the central nervous system (CNS), are 
less successful than those for primary tumors 1. Approximately 15%−40% of all cancers 
develop a CNS metastasis 2,3, which most commonly arises from lung cancer, melanoma, 
breast cancer, and colorectal cancer. Therapeutic monoclonal antibodies (mAbs) have 
revolutionized the treatment of cancer; however, their efficacy is limited in patients with 
CNS metastases due to insufficient mAb CNS delivery—typically 0.1% of the levels in 
plasma 4. By bypassing the blood-brain barrier (BBB) through intrathecal or intraventricular 
administration, mAb therapy has shown some effectiveness against CNS tumor metastases 
4–10
. However, direct CNS administration is invasive, with potential for neurotoxicity, and is 
limited by rapid efflux of antibodies from the CNS within hours 5,10,11. Therefore, novel 
approaches for mAbs delivery are preferable to maintain systemic therapeutic effect in the 
CNS with improved efficiency.
To date, various carrier vehicles for macromolecule delivery such as viral vectors, 
liposomes, cationic polymers, inorganic delivery systems, and other biomolecules have been 
explored to improve CNS delivery 12–14. Viral vectors are effective for CNS delivery in 
some settings but have potential safety concerns 15,16. Liposome-based protein delivery has 
been shown to penetrate the BBB, but with relatively low efficiency, biocompatibility, and 
stability 17,18. Polymer nanoparticles conjugated to target ligands with a variety of structures 
and morphologies have been used to form micelles through self-assembly, but in vivo 
instability, tissue-specific accumulations, and protein denaturation during complexing are 
problematic 19,20. Inorganic delivery systems, including gold nanoparticles 21,22 and 
mesoporous silica particles 23, are non-biodegradable and difficult to load or conjugate with 
macromolecules. Biomolecules, such as cell-penetrating peptides and antibodies, have 
improved the efficacy of macromolecule delivery, but degradation of cargo still hampers 
their therapeutic applications 24. The above approaches have shown promise, but drastic 
improvements are needed—especially in the systemic delivery of macromolecules into the 
CNS 19,25.
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Rituximab (RTX) for treatment of non-Hodgkin lymphoma (NHL) was the first anti-cancer 
antibody approved by the U.S. Food and Drug Administration. RTX binds to CD20+ 
lymphoma cells and induces cell death through complement-dependent cytotoxicity (CDC), 
antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis 26. RTX may also 
promote anti-lymphoma immune responses 27. The substantial benefits of RTX 
administration in treatments for systemic NHL are well-established, but treatment of primary 
and relapsed CNS lymphoma has not been effective through the intravenous route, likely due 
to the very low levels of systemic RTX entering the CNS 4. CNS involvement in NHL is 
relatively rare, but there is elevated risk in patients with immunodeficiency diseases 9 or 
renal, cardiac, lung, and liver transplants.
We demonstrate that compared to administration of native RTX, timed-release nanocapsule 
delivery of RTX achieves levels around 10-fold higher RTX concentration in the CNS 
following a single-course treatment and is maintained for at least 4 weeks, as opposed to 1 
week with native RTX. Furthermore, we developed a human NHL xenograft murine model 
for CNS metastases and show therapeutic efficacy of RTX nanocapsules against CNS 
lymphomas. In addition, using a humanized BLT mouse model, we demonstrate clearance of 
CNS lymphomas.
Results and discussion
Nanocapsules facilitate CNS penetration
We have developed a nanotechnology strategy whereby individual macromolecules are 
encapsulated within a thin polymer shell formed by in situ polymerization of monomers and 
stabilized by environmentally-responsive crosslinkers 28,29. Like a virion capsid, the 
polymer shell shields cargo from the environment and confers high resistance to 
denaturation, proteases, and nucleases, and determines the distribution of nanocapsules. 
Nanocapsules with polymer shells formed by neutral monomers with zwitterionic properties, 
2-methacryloyloxyethyl phosphorylcholine (MPC), exhibited broad biodistribution 30 and a 
long half-life 31. MPC is used in contact lenses and tested for use in coronary stents and 
other medical devices 32,33 and is inert, highly stable, resistant to protein adsorption, and 
lacks immunogenicity. We synthesized RTX nanocapsules with MPC monomers and 
glycerol dimethacrylate (GDMA) crosslinkers, which are efficiently degraded under acidic 
conditions but deteriorate very slowly under physiological conditions (termed n-
RTX(GDMA)).
We first evaluated the biodistribution and brain delivery efficiency of our nanoparticles 
without release of the RTX cargo under physiologic conditions using n-RTX(GDMA) 
(Supplementary Fig.1). Biodistribution of the nanocapsules was assayed by enzyme-linked 
immunosorbent assay (ELISA) after releasing RTX by acid treatment (pH5.4) at 4 ⁰C for 
overnight ex vivo. Higher levels of n-RTX(GDMA) were present in plasma by day 7. 
Importantly, more RTX released from n-RTX(GDMA) was observed in the brain and 
cerebrospinal fluid (CSF). Levels of released RTX in CSF were 1.7–5.5% the levels in 
plasma (5.5% on day 1, 1.7 % on day 7, and 3% on day21); native RTX was undetectable in 
CSF at all three points. This is consistent with the relative inability of antibodies to cross the 
BBB 4.
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To achieve proper release of mAb for therapeutic treatment, nanocapsules were designed to 
release cargo over time. This is accomplished by securing the polymer shell with mixed 
crosslinkers that are hydrolyzed gradually under physiological conditions (Fig.1A). MPC 
monomers are enriched around the surface of individual RTX molecules through 
electrostatic interactions, then hydrolysable crosslinker (Poly(DL-lactide)-b-Poly(ethylene 
glycol)-b-Poly(DL-lactide)-diacrylate triblock copolymers (PLA-PEG-PLA) and slowly-
hydrolysable crosslinker GDMA are associated by hydrogen bonding under physiological 
conditions. Subsequent polymerization in an aqueous solution wraps each molecule with a 
thin shell of polymer through in-situ free-radical polymerization. When PLA-PEG-PLA is 
hydrolyzed by body fluids, the nanocapsules dissociate and release encapsulated RTX. 
These nanocapsules have a relatively uniform, small diameter of 20–30 nm as measured by 
transmission electron microscope (TEM) (Supplementary Fig.2) and consist of a single-RTX 
molecule core-shell structure (Supplementary Fig.3). To sustain timed release in plasma at 
neutral pH, we mixed GDMA with PLA-PEG-PLA to achieve different release rates. 
Depending on the relative ratios of PLA-PEG-PLA (100%, 50%, 30%, and 10%), these 
nanocapsules released RTX at different rates under physiological conditions (Fig.1B): RTX 
nanocapsules with 50% PLA-PEG-PLA crosslinker (termed n-RTX) enabled gradual release 
over 7 days. Importantly, lower pH (pH 5.5–6.0) allowed accelerated RTX release (Fig.1C), 
which would facilitate quicker release of RTX in the lower pH tumor microenvironment 
34,35
 than in the bloodstream or healthy tissues.
We next examined the kinetics of RTX released from nanocapsules with 50% PLA-PEG-
PLA crosslinker in B6 mice (Fig.1D,E). Mice were injected with a single intravenous dose 
of either n-RTX or native RTX. Except for Day 1, where RTX was slightly lower in the n-
RTX group, there were comparable levels in plasma through Day 28. In contrast, 8 to 10-
fold enhancements of free RTX levels were observed in the CNS and brain tissue when 
delivered by n-RTX relative to native RTX. Mice treated with n-RTX had detectable levels 
of RTX in the CNS and brain for up to 4 weeks. Similar results were also confirmed in rats 
(data not shown). Immunohistochemical staining of rat brains treated with n-RTX showed 
normal microglia and astrocyte morphology (Supplementary Fig.4) 36,37. No significant 
elevation of ionized calcium-binding adapter molecule 1 (Iba1) in microglial cells nor glial 
fibrillary acidic proteins (GFAP) in astrocytes of rat brains treated with nanocapsules were 
observed compared to untreated control animals (Supplementary Fig.4B,C). These results 
provide proof of concept for penetration, release, maintenance, and safety of mAb 
nanocapsules in both plasma and CNS.
Encapsulated RTX effectively controls CNS lymphoma formation
Next, we compared anti-lymphoma efficacy of native RTX and n-RTX in a xenograft murine 
model. We first established a human NHL xenograft murine model that can consistently 
form CNS lymphomas with 2F7 cells, a cell line derived from AIDS-associated B-cell NHL 
38
. These 2F7 cells were marked with an mStrawberry reporter gene by a lentiviral vector. 
Individual sub-clones were tested for their ability to metastasize into the CNS. Two out of 
ten sub-lines formed CNS lymphomas within 7 weeks after intraperitoneal injection. 
Lymphoma cells were isolated from the brain of one of these sub-lines and re-adapted to cell 
culture. The resulting cell line, termed “2F7-BR44,” forms CNS lymphomas in 100% of 
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mice within 7 weeks following intraperitoneal injection (Supplementary Fig.5A) or 1–2 
weeks following tail vein injection of 2×106 cells (Supplementary Fig.5B). 2F7-BR44 cells 
maintain expression of four pan-B cell markers (CD19, CD20, CD22, and CXCR5) at levels 
comparable to the parental 2F7 cells (Supplementary Fig.6A). The cells are sensitive to 
apoptosis mediated by RTX, comparable to the parental cell line, and also sensitive to 
complement in vitro (Supplementary Fig.6B,C).
Lymphoma burden and therapeutic efficacy were quantified by evaluating the percentage of 
mStrawberry+ 2F7-BR44 cells in different tissues. CNS metastases generally arise later than 
those in systemic organs; without treatment, animals usually die from systemic 
complications. Mice with lymphoma show apparent signs of lymphoma burden such as 
weight loss, pale skin, anemia, and decreased activity. Once the lymphoma burden in CNS 
increases up to ~15%, as quantified by the percentage of mStrawberry+ in single cell 
fraction obtained from whole brain tissues following perfusion, mice show hind leg 
paralysis. Native RTX treatment significantly extended survival of mice engrafted with 2F7-
BR44 cells (Supplementary Fig.7B) and efficiently reduced lymphoma burden in bone 
marrow as well as to a lesser extent in spleen, but was ineffective in brain as well as lymph 
nodes (Supplementary Fig.7C).
We next compared the efficacy of native RTX versus n-RTX in controlling lymphoma 
formation in the brain. n-RTX improved the therapeutic efficacy of RTX against CNS 
metastases in the NHL murine model; in contrast, untreated animals required euthanization 
at week 3.5–4 due to severe anemia (Fig.2A). Treatment significantly improved mouse life 
span: native RTX-treated mice survived up to week 5, whereas half of the n-RTX-treated 
mice showed no symptoms of lymphoma formation in brain until the end time points (week 
5.5). Both native RTX and n-RTX capably suppressed lymphoma formation in bone marrow. 
In contrast, n-RTX significantly reduced lymphoma burden in the brain, whereas native RTX 
had no effect despite effective systemic control (Fig.2B). The correlation between controlled 
lymphoma growth and heightened RTX concentration illustrated by these results further 
demonstrates that RTX delivered via nanocapsules exerts control over CNS metastases.
Nanocapsules conjugated with CXCL13 can target lymphoma cells by binding to CXCR5
Ligands can be readily conjugated to the surface of nanocapsules to redirect them to specific 
targets; thus, targeting nanocapsules to lymphoma cells is predicted to increase RTX 
concentrations at the site of the lymphoma, enhancing potency and specificity of activity. To 
demonstrate the potential of ligand-mediated lymphoma targeting, we selected CXCL13: a 
chemokine belonging to the CXC family that interacts with CXCR5, a receptor expressed on 
mature B cells 39,40, and is associated with NHLs of B cell origin 41–43. In malignancies, 
CXCL13 has suspected involvement in metastasis of lymphoma cells 44,45; therefore, to 
assure accurate modelling of the metastatic environment, we evaluated CXCR5 expression 
in 2F7-BR44 cells and confirmed that they showed a similar level of CXCR5 expression to 
that of parental 2F7 cells (Supplementary Fig.6A). We then conjugated CXCL13 to the 
surface of nanocapsules at a molar ratio of approximately 1:1 (Supplementary Fig.8, n-
RTXCXCL13). This conjugation did not induce significant change on either particle size or 
surface charge of n-RTX (Supplementary Fig.9A,B).
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To evaluate the binding of CXCL13-conjugated nanocapsules, EGFP was used as a model 
protein for nanocapsule synthesis with GDMA crosslinkers which are slowly hydrolysable 
under physiological conditions (n-EGFP(GDMA) and n-EGFP(GDMA)CXCL13). We found that 
CXCL13 conjugation improved the specific binding of nanocapsules on 2F7-BR44 cells 
(Fig.3B, 2F7) while minimizing non-specific binding on non-targeted cells (Fig.3B, Jurkat); 
this specific binding of n-EGFP(GDMA)CXCL13 on 2F7-BR44 cells was further confirmed by 
flow cytometry (Fig.3C). Importantly, CXCL13 conjugation did not change the surface 
properties of MPC nanocapsules, maintaining resistance to cellular uptake. Similarly to n-
RTX(GDMA), n-RTX(GDMA)CXCL13 bound to 2F7-BR44 cells but was not internalized 
(Supplementary Fig.10). Biodistribution data showed that both n-RTX(GDMA) and n-
RTX(GDMA)CXCL13 systemically distributed in mice (Fig.3D), were delivered with uniform 
efficiency within the brain, and exhibited decreased accumulation in the liver, kidney, and 
lung—tissues known for showing non-specific accumulation of antibody (Fig.3E,F).
We next demonstrated the enhanced effectiveness of n-RTX conjugated with CXCL13 (n-
RTXCXCL13) in controlling lymphoma growth in a xenograft murine model. Compared to 
native RTX, there was significant improvement in the kinetics of RTX delivery released 
from both n-RTX and n-RTXCXCL13 into CSF and brain; minimal differences were noted 
between the two kinds of nanocapsules (Supplementary Fig.11A). Moreover, there were no 
clear liver or kidney toxicities over 4 weeks of nanocapsule treatment (Supplementary Fig.
11B). Importantly, compared to native RTX and n-RTX-treated animals, mice treated with n-
RTXCXCL13 showed improved survival rate (Fig.4A) and minimal CNS lymphoma 
formation until the end time points (Fig.4B). Greater amounts of n-RTXCXCL13 were 
observed in areas of lymphoma growth (Fig.4C,D), indicating that n-RTXCXCL13 
preferentially locates with 2F7-BR44 lymphoma in the brain. Besides lymphomas in brain, 
renal lymphoma and intraocular lymphoma were also observed in this NHL murine model. 
Unlike native RTX treatment, intraocular lymphoma was prevented by treatment with n-
RTX; however, nodules still formed on kidneys (Fig.4E). n-RTXCXCL13 showed clear 
colocalization with 2F7-BR44 cells in the kidney (Supplementary Fig.12) and exerted 
superior anti-lymphoma activity in both locations compared to native RTX or n-RTX (Fig.
4E).
Nanocapsules conjugated with CXCL13 improved therapeutic efficacy at different stages 
of lymphoma progression
To facilitate longitudinal analysis of lymphoma location and progression, the NHL mouse 
model was further adapted for optical imaging by marking 2F7-BR44 cells with a lentiviral 
vector expressing firefly luciferase (2F7-BR44-Luc). Following injection of D-luciferin, the 
substrate of luciferase, in vivo distributions and growth of 2F7-BR44-Luc cells were 
monitored by in vivo bioluminescence imaging over time (Supplementary Fig.13). 
Bioluminescence imaging in the NHL xenograft murine model indicated that 2F7-BR44 
cells initially migrated into the lungs after tail vein injection, followed by redistribution to 
CNS (brain and spinal cord) and bone marrow (BM) from sternum and femur within the first 
week. At week 2, signal intensity from lymphomas in the brain, spinal cord, sternum, femur, 
and kidneys increased.
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Based upon the kinetics of lymphoma formation, we conducted studies in which treatment 
was initiated after lymphoma formation. Mice were treated with native RTX or n-
RTXCXCL13 at different times: week 1 (Group I) and week 2 (Group II) post-injection of 
2F7-BR44-Luc cells. Treatment by n-RTXCXCL13 in both groups resulted in significant 
control of lymphoma burden relative to native RTX treatment, measured by bioluminescence 
per a defined area (Fig.5A,B). Survival of lymphoma-bearing mice was significantly 
extended by 1–2 weeks via n-RTXCXCL13 treatment compared to native RTX treatment in 
both Group I and II (Fig.5C,D). To quantify the difference in therapeutic efficacy between 
native RTX and n-RTXCXCL13, bioluminescence intensity (BLI) from 2F7-BR44-Luc cells 
in the whole body was compared every week after treatment (Fig.5E,F). In Group I, whole 
body therapeutic efficacy was similar in the first week post-treatment across both treatment 
types but was significantly improved by n-RTXCXCL13 later, suggesting more effective 
control of lymphoma burden by n-RTXCXCL13. In Group II, there was a significantly greater 
effect of n-RTXCXCL13 treatment, but less than in mice treated in Group I. To assess the 
impact upon CNS lymphomas, BLIs from the head area were quantified (Fig.5G,H). 
Treatment with n-RTXCXCL13 notably slowed and controlled CNS lymphoma burden in both 
groups. In Group II, where lymphomas had already formed in CNS before treatment, all 
mice with n-RTXCXCL13 showed a decrease in lymphoma burden at 1 week following 
treatment.
Nanocapsules conjugated with CXCL13 eliminated lymphoma in xenograft humanized BLT 
mice
The above NHL xenograft murine model uses immunodeficient mice in which the killing of 
2F7-BR44-Luc cells is likely to be primarily, if not exclusively, by induction of apoptosis. 
RTX is known to induce anti-lymphoma killing through multiple mechanisms in addition to 
apoptosis, including ADCC and CDC 26. Thus, the efficacy of RTX against CNS 
lymphomas in the NHL xenograft model is highly limited 46. We further evaluated n-
RTXCXCL13 in a humanized BLT (bone marrow/liver/thymus) murine model wherein human 
T cells, B cells, natural killer (NK) cells, and macrophages reconstitute; of these 
populations, both NK cells and macrophages can induce ADCC. Humanized BLT mice 
develop notably human NK and macrophage populations in tissues, including the brain 
47–50
. Consistent with a published study 51, we found substantial macrophage repopulation 
in the brains of these mice (data not shown). Humanized BLT mice were treated with native 
RTX or n-RTXCXCL13 at week 1 post-injection of 2F7-BR44-Luc cells and monitored for 
lymphoma growth for 12 weeks while unrelated antibody Herceptin (anti-human epidermal 
growth factor receptor (HER) 2) and n-HERCXCL13 were included as negative controls. 
Native RTX treatment showed effective therapeutic efficacy throughout the body except in 
brain, which resulted in paralysis on weeks 4–8; additionally, neither native HER nor n-
HERCXCL13 treatment showed any therapeutic effect (Fig.6A). In contrast, n-RTXCXCL13 
completely eliminated lymphomas in mice and initiated regression of CNS lymphomas, with 
no relapse observed even until the endpoint at week 13. Survival of lymphoma-bearing mice 
was significantly extended by n-RTXCXCL13 treatment (Fig.6B). The clearance of 
lymphomas was confirmed by flow cytometry of tissues (Fig.6C).
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We demonstrate that a single-course treatment of RTX encapsulated within an MPC-based 
nanocapsule designed to administer mAb by timed release results in CNS RTX 
concentrations up to 10-fold higher than native antibody and yields detectable levels for at 
least 4 weeks in a murine model. Using an NHL xenograft murine model, better penetration 
into the CNS allows control of CNS lymphoma formation. Three basic components were 
tuned to increase anti-lymphoma effects of RTX: 1) a polymer shell which allows longer 
systemic circulation and CNS penetration, 2) crosslinkers which stabilize the polymer shell 
and release mAb through timed hydrolysis, and 3) CXCL13 conjugated to the surface 
enabling targeting to CXCR5-expressing lymphoma cells. CNS penetration of the 
nanocapsules appears to be mediated by binding of choline and acetylcholine analogues of 
the nanocapsule polymer shell to choline transporters and acetylcholine receptors 52.
Enhanced RTX levels in the CNS could act to control local lymphoma growth through 
various effector mechanisms. Both CDC and ADCC function in the CNS 53–56, but are likely 
limited due to low antibody levels. In the NSG xenograft murine model, induction of 
apoptosis is likely to be the major mechanism for lymphoma cell elimination since 
complement components are absent; it is unclear whether murine microglia may contribute 
to ADCC activity 54. With limited effector functions, only partial control was achieved in 
xenografted NSG mice. By repeating studies in humanized BLT mice wherein human 
macrophages and NK cells differentiate, we demonstrated complete elimination of 
lymphomas both systemically and in the CNS. We suspect that the differences between these 
two murine models exist due to the presence of ADCC in the humanized BLT mice, which is 
absent in the standard xenograft model using NSG mice. Future studies will better elucidate 
the mechanisms responsible for lymphoma control and clearance.
Outlook
The strategy described here should be applicable to other therapeutic mAbs wherein CNS 
penetration is limited. For example, breast cancer patients under systemic Herceptin therapy 
often relapse with CNS metastases that are resistant to mAb therapy 7,57. By bypassing the 
BBB through intrathecal or intraventricular administration, mAb therapy for lymphoma and 
breast cancer has shown some effectiveness against CNS metastases 7,58. Our results suggest 
a potential non-invasive alternative treatment of CNS lymphomas as well as a potential 
prophylactic use of the nanocapsules against CNS metastases. Since the biodistribution of 
the mAb is conferred by the nanocapsules, not the cargo, any mAb (or protein) could be 
used. Anti-phosphorylcholine autoantibodies have been reported in mice 59 and humans 60, 
and could potentially affect the in vivo dynamics of nanocapsules generated with MPC, 
though we do not observe more rapid clearance relative to native mAb. We anticipate that 
further studies on the biodistribution and optimization of formulations through the 
engineering of polymers, crosslinkers and targeting ligands will further improve CNS 
delivery and therapeutic efficacy for CNS diseases.
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Methods
Synthesis of nanocapsules
Nanocapsules were synthesized with optimized modification for antibodies based on our 
previous reports31. Proteins (RTX or EGFP) were encapsulated via in situ polymerization at 
room temperature using MPC as the monomer, PLA-PEG-PLA and/or GDMA as the 
crosslinker, and ammonium persulfate and tetramethylethylenediamine as the initiator. 
Synthesized nanocapsules were dialyzed against PBS and purified by passing through a 
hydrophobic interaction column (Phenyl-Sepharose 4BCL). Detailed parameters, 
procedures, and characterization of the synthesis are provided in the Supplementary section.
Biodistribution studies
Biodistribution of native RTX and n-RTX was determined by monitoring the free RTX 
concentration in animal body fluids and perfused tissue homogenates. Briefly, C57BL/6 
mice were randomly divided into two groups and retro-orbitally injected at a dosage of 20 
mg/kg/mouse, a dose which has been reported as effective in an NHL xenograft murine 
model61. CSF was collected from a mouse under anesthesia by Ketamine and Xylazine (100 
mg/kg each). After CSF collection, this mouse was perfused with cold phosphate-buffered 
saline (PBS), euthanized, and organs were harvested. All perfused tissues were homogenized 
by vortexing with ceramic beads in PBS containing protease inhibitor cocktail.
Non-Hodgkin Lymphoma (NHL) mouse model with CNS metastases
Animal research described in the study was approved by the University of California, Los 
Angeles (UCLA)’s Chancellor’s Animal Research Committee (Institutional Animal Care 
and Use Committee [IACUC]), and was conducted in accordance with guidelines for 
housing and care of laboratory animals of the National Institutes of Health (NIH) and the 
Association for the Assessment and Accreditation of Laboratory Animal Care (AALAC) 
International. 2F7 cells were first marked with a fluorescent reporter gene by a lentiviral 
vector expressing mStrawberry. The 2F7 cells were then sub-cloned and tested individually 
for ability to metastasize into CNS. We selected clone 44 out of 10 clones, which showed 
stable brain metastatic ability. An NSG mouse received 2×106 mStrawberry+ 2F7 clone 44 
cells via intraperitoneal injection and showed brain metastasis 7 weeks post-injection (see 
Supplementary Fig.5A). Lymphoma cells were isolated from the brain metastatic site and 
adapted to cell culture to establish the 2F7-BR44 cell line. 2×106 of 2F7-BR44 cells were 
injected into NSG mice via lateral tail vein to establish an NHL xenograft murine model 
with CNS metastases.
MAb detection by ELISA
The concentration of RTX in animal body fluids (CSF and plasma) and tissue homogenates 
was measured by ELISA against RTX. 96-well plates were coated with 1 μg/mL of anti-
RTX antibody (diluted in sodium carbonate–bicarbonate buffer), followed by blocking with 
1% BSA/PBS for 2 hours at room temperature. Diluted RTX in PBST (0.1% Tween/PBS) 
from 0 to 500 ng/mL were then added and incubated for an hour at room temperature to 
obtain calibration curves. Animal body fluids and tissue homogenates containing 
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encapsulated RTX in non-degradable nanocapsules were treated with 100 mM sodium 
acetate buffer (pH 5.4) at 4ºC overnight, then used for ELISA measurement. Free RTX 
released from n-RTX was directly measured with animal body fluids and tissue 
homogenates. All animal samples were added to the well and incubated for an hour at room 
temperature. After five-times wash with PBST, peroxidase-conjugated anti-human Fc 
antibody was added and incubated for an additional hour at room temperature. The substrate 
3,3′,5,5′-Tetramethylbenzidine (TMB) solution was added and incubated until the 
appropriate color had developed. The reaction was stopped and absorbance at 450 nm was 
measured with a microplate reader.
Anti-lymphoma efficacy of RTX in the NHL xenograft murine model with CNS metastases
2F7-BR44 cells (2×106/animal) were injected into NSG mice via tail vein. Five days after 
2F7-BR44 cell injection unless otherwise stated, mice were treated with a single course of 
native RTX, n-RTX, or n-RTX conjugated with CXCL13 (n-RTXCXCL13) via retro-orbital 
vein injection (4mg/kg/day for 5 days). Mice were sacrificed when in critical condition due 
to lymphoma burden or at the end time points decided in experiment design. The mice were 
perfused with cold PBS, euthanized, and organs were harvested for single-cell isolation from 
tissues. Cells from target tissues were stained with anti-human CD45 and CD19, then 
analyzed by flow cytometry.
In vivo imaging to monitor lymphoma progression
2F7-BR44 cells were gene marked with a lentiviral vector expressing firefly luciferase, then 
luciferase-expressing cells were selected by a week of Zeocin treatment (200 μg/ml) (2F7-
BR44-Luc). 2F7-BR44-Luc cells (2×106/animal) were injected into NSG mice or BLT 
humanized mice via tail vein. Humanized mice were prepared as previously described with 
modifications 62–64. Human fetal tissue was purchased from Advanced Biosciences 
Resources (Alameda, CA) without identifying information, which did not require 
Institutional Review Board approval for its use. Six-week-old NSG mice were administered 
Busulfan (35 mg/kg) intraperitoneally. Twenty-four hours later, the mice were implanted 
with a portion of human fetal thymus combined with fetal liver-derived CD34+ cells 
solidified in Matrigel under the kidney capsule and also via retro-orbital vein injection. After 
the human blood cell reconstitution in peripheral blood, 2F7-BR44 cells (2×106/animal) 
were injected into humanized BLT mice via tail vein to establish xenograft humanized BLT 
mice. Lymphoma formation was monitored by in vivo bioimaging using the IVIS Lumina II 
in vivo imaging system (PerkinElmer, Waltham, MA). In vivo bioluminescence imaging was 
performed following subcutaneous injection of 4.5 mg D-luciferin (Pierce, Woodland Hills, 
CA). Mice were imaged at the signal plateau (10 minutes post-D-luciferin injection) under 
isoflurane anesthesia. Lymphoma burden was quantified as the total photon flux per second 
within a region of interest (ROI) (whole body or head area) of the mouse; ROIs were 
identically sized for all measurements. Sensitivity settings were adjusted at each time point 
to maintain 250–5000 counts per pixel for humanized mice and 500–5000 counts per pixel 
for NSG mice.
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Statistical analyses
Results are expressed as mean ± standard deviations (SDs). Statistical significance is 
presented with a p-value calculated via GraphPad Prism. The significance of survival-curve 
data was compared with a log-rank test. All other significance comparisons between groups 
were calculated by one-tailed unpaired t-test with Welch’s correction.
Reporting summary
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Data availability
The authors declare that all data supporting the results in this study are available within the 
paper and its Supplementary Information. Source data collected in this study are available 
from the corresponding author upon request.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1 |. Timed-release nanocapsules facilitate brain delivery of RTX in mice.
a, Scheme of the synthesis and release of timed-release RTX nanocapsules by (I) enriching 
MPC monomer and hydrolysable crosslinker PLA-PEG-PLA and slowly hydrolysable 
crosslinker GDMA around a RTX molecule, (II) in situ polymerization of the monomer and 
crosslinkers forming a thin shell of polymer around a RTX molecule, and (III) releasing 
RTX when polymer shells are degraded under physiological conditions by hydrolysis of the 
crosslinkers. b, RTX nanocapsules were synthesized with mixed crosslinkers GDMA and 
PLA-PEG-PLA, at which the ratios of PLA-PEG-PLA were 100%, 50%, 30%, and 10%. 
Twenty-five μg of each nanoencapsulated RTX or native RTX (RTX) was added into 1mL of 
PBS and incubated at 37 °C for 1 week. The concentration of free RTX was measured by 
ELISA. c, The release rates of RTX nanocapsules with 50% PLA-PEG-PLA crosslinkers 
were compared in PBS buffers with various pH values presenting physiological conditions 
(pH=7.4 and 7) and acidic pH conditions (pH=6.5, 6, and 5.5). Twenty-five μg of each 
sample were added into 1mL of PBS buffer and incubated at 37 °C for up to 1 week. The 
concentration of free RTX was measured by ELISA. Data are shown as means ± standard 
deviations (SDs) of biological duplicates. The statistical significance of the pH7.4 
(physiological condition) was assessed by p-value, calculated by one-tailed paired t-test with 
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Welch’s correction. d,e, B6 mice (n=3) were administrated with 20 mg/kg of native RTX or 
RTX nanocapsules with 50% PLA-PEG-PLA crosslinkers (n-RTX) via retro-orbital vein. 
Plasma, CSF (b), and perfused brain tissue samples (c) were collected and concentrations of 
free RTX were measured by ELISA on days 1, 7, and 28. Data are shown as means ± SDs of 
biological triplicates. The statistical significance of the data for the native RTX group was 
assessed via p-values (provided), calculated by one-tailed unpaired t-test with Welch’s 
correction.
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Fig. 2 |. Nanocapsulation enhances anti-lymphoma activity of RTX against CNS lymphomas in 
the 2F7-BR44 murine xenograft model.
2F7-BR44 cells (2×106/animal) in 100 μL Hank’s balanced salt solution were injected into 
NSG mice via tail vein. Five days after injection, mice were randomly separated into three 
groups: no treatment (n=3), native RTX and n-RTX treatment (n=4). Native RTX or n-RTX 
was injected via retro-orbital vein at 4 mg/kg/day for 5 days. a, Kaplan-Meier survival 
curves of the mice in each group were plotted relative to the number of weeks after 2F7-
BR44 cell injection. The statistical significance was shown with a p-value calculated by the 
log-rank test. b, Tissue distribution of 2F7-BR44 cells in blood, perfused bone marrow (BM) 
and brain was analyzed by flow cytometry at endpoints. Data are shown means ± SDs of 
biological triplicates (No treatment) or quadruplicates (RTX or n-RTX). Statistical 
significance was calculated with respect to the no treatment group using a p-value calculated 
by one-tailed unpaired t-test with Welch’s correction. #: Note that the apparent higher tumor 
burden in brain of the native RTX group compared to the no-treatment group is due to one-
week longer duration of the native RTX group versus the no-treatment group which were 
euthanized one week earlier due to massive systemic tumor growth.
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Fig. 3 |. CXCL13 conjugation mediates 2F7-BR44 cell specific nanocapsule targeting without 
affecting overall biodistribution.
a, Scheme of CXCL13 conjugation on n-RTX(GDMA). CXCL13 was conjugated to n-
RTX(GDMA) at a molar ratio of 1:1 through copper-free click chemistry. b,c, EGFP 
nanocapsules with 100% slowly hydrolysable crosslinkers, GDMA, (n-EGFP(GDMA)) 
conjugated with or without CXCL13 (0.1 mg/ml each) were incubated 1 hour at 37⁰C with a 
mixed cell population of 2F7-BR44 cells (2F7, mStrawberry+) and Jurkat T cells (Jurkat, 
BFP+). The binding of each nanocapsule on each cell population was analyzed on Leica 
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DMi8 inverted microscope (b) or on BD LSRFortessa (c). The same experiments were 
repeated independently three times. d,e, NSG mice (n=3) were administrated with 20 mg/kg 
of carboxytetramethylrhodamine (TAMRA)-labelled RTX, n-RTX(GDMA) and n-
RTX(GDMA)CXCL13 via tail vein. Fluorescence images of whole body (d) and each organ (e) 
were taken 1 day after administration. f, NSG mice (n=3) were administrated with 20 mg/kg 
of gold-nanoparticle labelled RTX, n-RTX(GDMA) and n-RTX(GDMA)CXCL13 via tail vein. 
Brain tissues were obtained 1 day after administration and processed for 
immunohistochemical analysis. Gold nanoparticles in paraffin sections were analyzed 
following silver enhancement, in which present as black depositions. Bar=50 μm.
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Fig. 4 |. CXCL13 conjugation improves anti-lymphoma activity of n-RTX.
a,b, 2F7-BR44 cells were injected to NSG mice via tail vein (2×106/animal). Five days after 
the injection, mice were randomly separated into three groups (n=5): native RTX, n-RTX, 
and n-RTXCXCL13. Each form of RTX was administrated via retro-orbital injection at 
4mg/kg/day for 5 days. Kaplan-Meier survival curves of the mice in each group were plotted 
relative to the number of weeks after 2F7-BR44 cell injection (a). Statistical significance 
was shown with a p-value calculated by the log-rank test. Percentages of 2F7-BR44 cells in 
the brain were analyzed by flow cytometry at endpoints following cardiac perfusion (b). The 
statistical significance was calculated to the native RTX group using a p-value calculated by 
one-tailed unpaired t-test with Welch’s correction. Data are shown means ± SDs of 
biological quintuplicates. c,d, Localizations of gold-labelled n-RTX(GDMA) with or without 
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CXCL13 conjugation were analyzed in the brain of 2F7-BR44 xenograft NSG mice (n=3) 3 
weeks after xenograft. One day after administration of gold-labelled n-RTX(GDMA) or n-
RTX(GDMA)CXCL13 via retro-orbital injection, brain tissue samples were processed for 
immunohistochemical analysis (c). Gold nanoparticles in paraffin sections were analyzed 
following silver enhancement, presented as black depositions. 2F7-BR44 cells were stained 
with anti-human Ku80 antibody and rhodamine red-X anti-rabbit IgG. The nuclei were 
stained by 4′,6-diamidino-2-phenylindole (DAPI). Asterisks indicate the tumor site while 
the white dash curves illustrate the boundary of tumor-normal parenchyma. Bar=25 μm. The 
average counts of gold-labelled n-RTX(GDMA) or n-RTX(GDMA)CXCL13 per mm2 from 5 
spots in representatives in Fig.4C (total counts from samples administrated with n-
RTX(GDMA) or n-RTX(GDMA)CXCL13 are approximately 11,000, respectively) in both the 
tumor site and normal tissue site were quantified by ImageJ (d). The statistical significance 
was calculated to normal tissue using a p-value calculated by one-tailed unpaired t-test with 
Welch’s correction. e, Representative images of intraocular lymphoma and lymphoma 
surrounding the kidney in each group.
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Fig. 5 |. CXCL13 conjugation improves anti-lymphoma activity of n-RTX at different stages of 
lymphoma progression.
CXCL13 was conjugated to n-RTX at a molar ratio of 1:1 through copper-free click 
chemistry (n-RTXCXCL13). 2F7-BR44 cells expressing firefly luciferase (2F7-BR44-Luc) 
were injected to NSG mice via tail vein (2×106/animal) (a-h). Mice were randomly 
separated into four groups (n=4): native RTX or n-RTXCXCL13 treatment at week 1 (a,c,e,g, 
Group I) or week 2 (b,d,f,h, Group II) after 2F7-BR44-Luc cell injection. Each form of RTX 
was injected via retro-orbital vein at 4 mg/kg/day for 5 days. a,b, The tumor progression and 
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metastasis status were monitored weekly by using bioluminescence imaging on IVIS 
Lumina II In Vivo Imaging system. Red arrows show the treatment time in each figure. 
Expansion and metastasis status of 2F7-BR44-Luc cells in NSG mice treated with native 
RTX or n-RTXCXCL13 at week 1 (Group I) or week 2 (Group II) as visualized by 
bioluminescence imaging. The red X boxes represent deceased mice. Sensitivity settings 
were adjusted at each time point to maintain 500–5000 counts per pixel and assigned the 
same color scale for both groups. c,d, Kaplan-Meier survival curves of the mice in each 
group were plotted relative to the number of weeks after 2F7-BR44-Luc cell injection. e,f, 
The bioluminescence intensity (BLI) in the whole body was compared between mice with 
treatment by native RTX and n-RTXCXCL13 in both groups and expressed in photons per 
second per square centimeter per steradian (p/s/cm2/sr). g,h, The BLI from head area was 
compared between mice with treatment by native RTX and n-RTXCXCL13 in both groups. 
Data are shown means ± SDs of biological quadruplicates. Statistical significance based on 
the native RTX group using a p-value was calculated by one-tailed unpaired t-test with 
Welch’s correction.
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Fig. 6 |. n-RTXCXCL13 exhibits superior anti-lymphoma activity against CNS lymphomas in the 
2F7-BR44-Luc cell xenograft humanized mice.
2F7-BR44-Luc cells (2×106/animal) were injected into humanized BLT mice generated from 
two independent donors (Donors I and II) via tail vein (a-c). Mice were randomly separated 
into two groups for treatment by native RTX or n-RTXCXCL13 at week 1 after the injection. 
Each form of RTX was administrated via retro-orbital vein at 4 mg/kg/day for 5 days. The 
tumor progression status was tracked weekly using bioluminescence imaging on IVIS 
Lumina II In Vivo Imaging system. a, Biodistribution of 2F7-BR44-Luc cells in humanized 
mice treated with native RTX or n-RTXCXCL13 at week 1 as visualized by luciferase 
bioimaging. The red X boxes represent deceased mice. Sensitivity settings were adjusted at 
each time point to maintain 250–5000 counts per pixel and assigned the same color scale for 
all treatment groups. b, Kaplan-Meier survival curves of the mice were plotted relative to the 
number of weeks after injection. Necropsies were performed at the end of the experiment 
(week 13). The statistical significance was shown with a p-value calculated by the log-rank 
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test. c, Percentages of 2F7-BR44-Luc cells in tissues were assessed by flow cytometry 
following cardiac perfusion at the endpoints. HER: naive Herceptin. n-HER: Herceptin 
nanocapsule. The statistical significance was calculated for all tissues from the native RTX 
group using a p-value, calculated by one-tailed unpaired t-test with Welch’s correction.
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